Sangamo Therapeutics Q3 net loss $53.2M; revenue down, Fabry gene therapy expands

SANGAMO THERAPEUTICS, INC

2022-Q3 EPS reported -$0.93 revenue$84,069,000

Q3 net loss $53.2M ($0.34/shr) vs $47.7M ($0.33/shr) prior year; revenue $26.5M down from $28.6M.
Cash $350.3M at Sep 30 (Dec 31: $464.7M); raised $75.1M net from ATM Jan-Oct 2022.
FY2022 guidance narrowed: GAAP op expenses $315-325M, non-GAAP $280-290M (excl ~$35M SBC).
Fabry gene therapy STAAR expansion: 5 patients dosed at 5e13 vg/kg, including first two females; Phase 3 prep ongoing.
Hemophilia A (Pfizer) Phase 3 AFFINE trial recruitment resumed; pivotal readout expected H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANGAMO THERAPEUTICS, INC reported third quarter ended September 30, 2022 results: revenue 26.5 million, net income 53.2 million (net loss), EPS 0.34 per share (net loss).

Period: third quarter ended September 30, 2022
Revenue: 26.5 million
Net income: 53.2 million (net loss)
EPS: 0.34 per share (net loss)
Result: reported results

Exact text from the filing

Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. Revenues Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001628280-22-028167

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.